AOCNP PRACTICE EXAM QUESTIONS
& VERIFIED ANSWERS (A+
GUARANTEE)
1. A patient with high-risk Tumor Lysis Syndrome (TLS) is preparing for induction
chemotherapy. Which medication is most appropriate for prevention of hyperuricemia in this
setting?
A. Rasburicase
B. Allopurinol
C. Febuxostat
D. Acetazolamide
Answer: A
Conceptual Explanation: For high-risk patients, Rasburicase is indicated as it rapidly
converts existing uric acid to allantoin, whereas allopurinol only prevents the formation of
new uric acid.
2. Which of the following describes the recommended screening for an individual with a
confirmed MLH1 mutation (Lynch Syndrome)?
A. Colonoscopy every 5 years starting at age 40.
B. Annual fecal occult blood test starting at age 30.
,C. Sigmoidoscopy every 3 years starting at age 35.
D. Colonoscopy every 1-2 years starting at age 20-25.
Answer: D
Conceptual Explanation: Lynch Syndrome guidelines recommend colonoscopy every 1-2
years beginning between ages 20 and 25 (or 2-5 years before the earliest colon cancer
diagnosis in the family).
3. A patient receiving Pembrolizumab presents with Grade 3 diarrhea (increase of >= 7 stools
per day over baseline). What is the priority intervention?
A. Hold therapy and initiate corticosteroids (1-2 mg/kg/day prednisone).
B. Continue therapy and start Loperamide.
C. Decrease the dose of Pembrolizumab by 50%.
D. Permanent discontinuation and start Infliximab immediately.
Answer: A
Conceptual Explanation: Grade 3 immune-related colitis requires holding the checkpoint
inhibitor and initiating high-dose systemic corticosteroids.
4. In the TNM staging system, what does a ‘pT3’ designation indicate?
A. Pathological staging of the primary tumor after surgical resection.
B. Primary tumor size based on radiological imaging.
C. Nodes are positive for metastatic disease.
, D. Clinical stage 3 based on physical exam.
Answer: A
Conceptual Explanation: The prefix ‘p’ denotes pathological staging, which is determined
by the examination of the surgical specimen.
5. Which molecular marker is essential to test in a patient with metastatic colorectal cancer
before prescribing EGFR inhibitors like Cetuximab?
A. RAS mutation status (KRAS/NRAS)
B. ALK rearrangement
C. HER2 amplification
D. BRAF V600E only
Answer: A
Conceptual Explanation: EGFR inhibitors are only effective in patients with RAS wild-type
tumors; mutations in KRAS or NRAS predict resistance to these therapies.
6. A patient with Multiple Myeloma presents with a new onset of hypercalcemia, renal
insufficiency, and anemia. These findings are collectively known as:
A. CRAB criteria
B. Hyperviscosity Syndrome
C. Tumor Lysis Syndrome
D. Bence-Jones phenomenon
& VERIFIED ANSWERS (A+
GUARANTEE)
1. A patient with high-risk Tumor Lysis Syndrome (TLS) is preparing for induction
chemotherapy. Which medication is most appropriate for prevention of hyperuricemia in this
setting?
A. Rasburicase
B. Allopurinol
C. Febuxostat
D. Acetazolamide
Answer: A
Conceptual Explanation: For high-risk patients, Rasburicase is indicated as it rapidly
converts existing uric acid to allantoin, whereas allopurinol only prevents the formation of
new uric acid.
2. Which of the following describes the recommended screening for an individual with a
confirmed MLH1 mutation (Lynch Syndrome)?
A. Colonoscopy every 5 years starting at age 40.
B. Annual fecal occult blood test starting at age 30.
,C. Sigmoidoscopy every 3 years starting at age 35.
D. Colonoscopy every 1-2 years starting at age 20-25.
Answer: D
Conceptual Explanation: Lynch Syndrome guidelines recommend colonoscopy every 1-2
years beginning between ages 20 and 25 (or 2-5 years before the earliest colon cancer
diagnosis in the family).
3. A patient receiving Pembrolizumab presents with Grade 3 diarrhea (increase of >= 7 stools
per day over baseline). What is the priority intervention?
A. Hold therapy and initiate corticosteroids (1-2 mg/kg/day prednisone).
B. Continue therapy and start Loperamide.
C. Decrease the dose of Pembrolizumab by 50%.
D. Permanent discontinuation and start Infliximab immediately.
Answer: A
Conceptual Explanation: Grade 3 immune-related colitis requires holding the checkpoint
inhibitor and initiating high-dose systemic corticosteroids.
4. In the TNM staging system, what does a ‘pT3’ designation indicate?
A. Pathological staging of the primary tumor after surgical resection.
B. Primary tumor size based on radiological imaging.
C. Nodes are positive for metastatic disease.
, D. Clinical stage 3 based on physical exam.
Answer: A
Conceptual Explanation: The prefix ‘p’ denotes pathological staging, which is determined
by the examination of the surgical specimen.
5. Which molecular marker is essential to test in a patient with metastatic colorectal cancer
before prescribing EGFR inhibitors like Cetuximab?
A. RAS mutation status (KRAS/NRAS)
B. ALK rearrangement
C. HER2 amplification
D. BRAF V600E only
Answer: A
Conceptual Explanation: EGFR inhibitors are only effective in patients with RAS wild-type
tumors; mutations in KRAS or NRAS predict resistance to these therapies.
6. A patient with Multiple Myeloma presents with a new onset of hypercalcemia, renal
insufficiency, and anemia. These findings are collectively known as:
A. CRAB criteria
B. Hyperviscosity Syndrome
C. Tumor Lysis Syndrome
D. Bence-Jones phenomenon
